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Abstract  16 
Daily rhythms in physiology significantly modulate drug pharmacokinetics and 17 
pharmacodynamics according to the time-of-day, a finding that led to the 18 
concept of chronopharmacology. The importance of biological clocks for 19 
xenobiotic metabolism has gained increased attention with the discovery of 20 
the molecular circadian clockwork. Mechanistic understanding of the cell-21 
autonomous molecular circadian oscillator and the circadian timing system as 22 
a whole has opened new conceptual and methodological lines of investigation 23 
to understand (1) the clock’s impact on daily variations of a specific drug’s or 24 
environmental substance’s effects and/or side-effects, and (2) how clock-25 
controlled pathways are coordinated within a given tissue or the whole body. 26 
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Today, there is an increased understanding of the circadian modulation of 27 
drug effects. Thus, the circadian coordination of Phase I, II and III xenobiotic 28 
metabolism can be viewed as an adaptive and anticipatory time mechanism, 29 
which most efficiently help increase xenobiotic water solubility and excretion. 30 
Interestingly, the circadian clock itself has been identified as a target for 31 
pharmacotherapy. Indeed, several molecular strategies are being developed 32 
to treat disease-dependent and drug-induced clock disruptions in humans.  33 
The Role of the Circadian Timing System in Xenobiotics detoxification 34 
Recent scientific evidence highlights the critical role of circadian rhythms for 35 
the metabolism and effects of xenobiotics (see Glossary), including drugs as 36 
well as environmental toxicants (Figure 1). Since 2011, there has been 37 
increased awareness on the regulation of circadian rhythms in pharmacology 38 
or toxicology. Conceptual and methodological progress has enabled the 39 
tracking of circadian patterns in cells, tissues, experimental animals and 40 
human beings [1-6]. These new insights have improved our understanding of 41 
the underlying molecular mechanisms and systems level organisation of the 42 
regulatory circuits, which modulate cellular metabolism and proliferation 43 
during the course of a 24 h day [7-9]. 44 
It has long been known that the Circadian Timing System (CTS) accounts 45 
for time-varying effects of xenobiotics with up to 10-fold magnitude, according 46 
to the timing of exposure, supporting the need for an increased understanding 47 
of chronopharmacology and chronotoxicology [10-12]. Highly reproducible 48 
24 h variation in drug toxicities has been documented in mice or rats kept in 49 
regular alternations of 12 h of light and 12 h of darkness (LD 12:12), as well 50 
as in constant darkness, thus unmasking possible direct effects of light on 51 
various endogenous and metabolic rhythms, e.g. cortisol [13]. However, 52 
animal species, strain, sex, age, fertility, as well as yearly and other biological 53 
cycles can represent additional sources of variability. Results from 54 
experimental chronopharmacology studies have led to investigate the 55 
relevance of time of dosing on the effects drugs or treatments may have in 56 
humans. Drug chronopharmacology usually displays opposite 24 h patterns in 57 
nocturnal rodents when compared to people, whose circadian physiology and 58 
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molecular clock gene expression differ by nearly 12 h relative to the light-dark 59 
schedule [14]. Recent experimental data using targeted anticancer agents 60 
have further determined that both circadian timing and drug dose play 61 
important roles in the determination of systemic exposures and therefore, of 62 
the pharmacologic effects (Table 1). Clinical trials including randomized 63 
Phase III studies or meta-analyses of chronotherapy schedules have resulted 64 
in up to five-fold better drug tolerability and a doubling in drug efficacy as 65 
compared to conventional non-time-stipulated treatment schedules 66 
[15](Table 2). By contrast, a number of randomized comparisons between 67 
morning and evening dosing times have demonstrated similar rates of 68 
adverse events and/or efficacy for several medications [16-19]. This suggests 69 
that either the optimal timing was missed in the study design, excessive dose 70 
levels were tested, or differences between patients led to an underestimation 71 
of the timing effect. Indeed, experimental and clinical data have revealed 72 
broad inter-individual CTS differences, resulting in different chronotoxicity 73 
profiles [6, 20]. Such differences can result from genetically-determined 74 
“chronotypes” as well as from epigenetic changes, age, sex, lifestyle, 75 
disease or pharmacological treatment [21-24]. Moreover, circadian disruption 76 
has emerged as a novel concept, identifying a lack of proper coordination 77 
between different components of the CTS as a contributing factor for 78 
developing cancer, metabolic syndrome and cardiovascular or infectious 79 
diseases [25-29]. Circadian disruption has further been associated with 80 
occupational shift-work [30]. It has also been linked to poor disease 81 
outcomes, especially in cancer patients [31]. The identification of subjects with 82 
different, yet functional CTS, and subjects with disrupted circadian rhythms 83 
have fostered the idea that circadian clocks could be therapeutically targeted 84 
[32]. This review focuses on the recent progress that has been made in 85 
identifying the mechanisms underlying the interactions between the CTS, 86 
disease and pharmacotherapy.  87 
Dosing-time Dependencies of Xenobiotic Effects 88 
Drug development aims to define a recommended dose for a potential new 89 
compound based on the majority of individual subjects, irrespective of timing, 90 
sex, age, lifestyle or comorbidities. However, unanticipated or overwhelming 91 
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adverse events represent severe limitations, resulting in both drug attrition 92 
[33, 34] and post-marketing withdrawal of several otherwise effective 93 
medications [35, 36]. Moreover, some countries, such as the UK, are now 94 
terminating the reimbursement of several medications (including anticancer 95 
drugs), despite demonstrated efficacy and safety in randomized Phase III 96 
trials, or their approved use by American, European, and other 97 
national/international regulatory authorities [37, 38]. An alleged rationale is 98 
that the toxicities of these new agents sometimes outweigh the slight benefits 99 
in efficacy at a population level, thus making these new treatments too costly 100 
for the healthcare system. As a result, medication safety represents a crucial 101 
challenge that needs to be prioritized and addressed with new concepts and 102 
methods at all stages of drug development and post-market approval. A large 103 
body of evidence, from mice to patients, supports the notion that 104 
chronopharmacology could indeed help minimize adverse events through the 105 
identification of optimally-timed drug delivery. An additional concern is the 106 
impact of circadian disruption (as observed in occupational shift-work), on an 107 
organism’s response to and detoxification of environmental xenobiotics. 108 
In past decades, the majority of chronopharmacology and chronotoxicology 109 
research has focused on the determination of xenobiotic exposure times 110 
leading to either highest or lowest toxicity or efficacy in rodents [10, 11]. 111 
Chronotoxicology or chronopharmacology measures have been established 112 
for many substances and marketed drugs in laboratory animals and/or human 113 
beings. Human chronopharmacology studies have further established dosing 114 
time dependencies for over 300 medications of all classes, including clinical 115 
validation of timing effects in randomized Phase III trials for a few of them [15, 116 
39](Table 2). Moreover, an improved mechanistic understanding of the CTS in 117 
addition to obtaining better tools for continuously monitoring the CTS at the 118 
molecular level and in real-time, provides proof-of-principle data for in vitro 119 
chronopharmacology testing (see below).  120 
The circadian timing system (CTS) 121 
The generation of circadian oscillations has been shown to occur at the level 122 
of the single cell. The molecular mechanism of this cell-autonomous 123 
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transcriptional/translational feedback loop has been largely elucidated, 124 
although further levels of control are still being discovered (Text Box 1). In 125 
multi-cellular organisms, all of these individual cellular clocks are coordinated 126 
by a central pacemaker that receives environmental light input and feedback 127 
from peripheral oscillators. In mammals, the suprachiasmatic nuclei (SCN) of 128 
the hypothalamus have been identified as this central pacemaker [40], which 129 
orchestrates behavioural and physiological rhythms like rest/activity, body 130 
temperature, and hormonal patterns, such as the 24-h cortisol rhythm in 131 
human subjects [41]. The inputs and feedbacks that provide time cues to the 132 
SCN are mediated through a variety of neuropeptides or direct axonal contact 133 
[41].  134 
Elucidating the dynamic relative contributions of peripheral and central 135 
clocks in physiology and pathophysiological alterations has only been 136 
feasible through the use of in vivo real-time bioluminescence recording in 137 
freely moving mice [4]. Most likely, multiple other processes are involved in 138 
the synchronisation of peripheral clocks. Even in the absence of the SCN or a 139 
tissue-intrinsic clock, some metabolic or proliferation pathways are still 140 
“driven” by these yet unknown signals, and/or an organism’s surrounding 141 
rhythmic physiology [4, 42, 43].  142 
Depending on the adaptation of a species, feedback signals from the 143 
periphery may have variable effects on the SCN. Some non-photic signals 144 
such as physical activity have great impact on the central pacemaker in 145 
specific rodent models [44], and possibly in human individuals, too. However, 146 
non-photic signals compete with light signals in terms of adaptation [45-47]. 147 
Most species show entrainment to food as a time cue. In mice, the liver has 148 
been shown to reset its clock based on the timing of food intake, independent 149 
of SCN signalling [48, 49]. Of note, food anticipatory activity is SCN 150 
independent in rodents and remains intact in BMAL1 but not PER2 deficient 151 
mice [50, 51]. Interestingly, recent evidence suggests that it is hepatic Per2 152 
regulated b-hydroxybutyrate production dependent [52].  153 
Importantly, food availability has also been shown to compete with light-154 
dependent signals coming from the SCN, and can lead to a situation where 155 
the SCN and liver clocks are uncoupled from each other [4, 53]. Such 156 
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uncoupling due to mistimed sleep has also been found in mouse under 157 
simulated “shift-work schedules”, and was suggested to be associated with 158 
metabolic disruption [54]. In fact, mistimed food intake has been shown to 159 
lead to obesity and metabolic syndrome in mice and human subjects [55-57]. 160 
Critical importance of peripheral clocks 161 
A developing and important question about peripheral clocks is what their 162 
impact on physiological processes is and therefore, also on what their role is 163 
in the modulation of pharmacotherapy. For example, the phase of the liver 164 
intrinsic clock is important for drug metabolism. For instance, the rhythm in 165 
acetaminophen toxicity with high toxicity during the night but low toxicity 166 
during the day is critically dependent on the hepatocyte circadian clock. Mice 167 
with liver-specific ablation of BMAL1 or CLOCK lack a rhythm in 168 
acetaminophen liver toxicity [58, 59]. Daytime feeding inverts this rhythm in 169 
nocturnal rodents, which mostly feed during the night phase, leading to high 170 
toxicity of acetaminophen during the day [60]. This illustrates that if peripheral 171 
tissue-intrinsic clocks regulate key steps of a molecular pathway, the 172 
deregulation of tissue clocks might represent an important pathological focus 173 
and lead to new potential pharmacotherapeutics. 174 
Furthermore, peripheral tissue clocks have been shown to be essential for 175 
proper physiological function in mice; even if all other peripheral clocks and 176 
the central pacemaker are intact. Most of this work has been carried out by 177 
selectively deleting clock function in specific organs or cell populations. For 178 
instance, genetic ablation of the circadian clock in pancreatic beta cells-179 
specific BMAL1 deficient mice has been shown to lead to type II diabetes [61, 180 
62]. Similarly, cardiac functions like myocardial contractility are impaired in α-181 
myosin heavy chain-ClockΔ19 knock in mice without a functional clock in 182 
cardiomyocytes [63]. Krüppel-like factor 15 (Klf15) is thought to link the 183 
circadian oscillator to the regulation of cardiac potassium channels important 184 
for cardiac repolarisation, and therefore ventricular arrhythmias in mice 185 
because cardiomyocyte-specific Klf15 deficient or overexpressing mice do not 186 
show circadian QT interval regulation [64]. Even the local disruption of 187 
peripheral clocks in the brain has important implications for the whole 188 
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organism. Deleting the circadian clock mechanism in histaminergic neuron 189 
populations in mice by locally deleting BMAL1 expression has been shown to 190 
alter histamine brain levels and consequently lead to sleep fragmentation and 191 
shallower NREM sleep [65]. Cell-intrinsic clocks in various immune cell 192 
populations have been shown to be of functional importance for time-of-day 193 
variations in both innate and adaptive immune functions [66-69]. Most 194 
recently, the circadian clock in pulmonary epithelial club cells was found to 195 
modulate recruitment of neutrophils to the lungs in response to a bacterial 196 
challenge. In wild-type mice circadian expression of the chemokine Cxcl5 in 197 
club cells and systemic glucocorticoid levels modulate neutrophil recruitment. 198 
In mice with BMAL1 deficient bronchiole cells, however, constant CXCL5 199 
increases inflammatory responses after bacterial challenges, despite 200 
persistent circadian glucocorticoid rhythms [68]. Of note, simulated shift-work 201 
in human volunteers disrupts the coupling between rhythms in cytokine 202 
secretion and relative abundance of monocytes and T-lymphocytes [70].  203 
Such non-exhaustive list of examples illustrates the functional importance of 204 
tissue intrinsic clocks and emphasizes the potential impact of circadian 205 
disruption. It remains to be seen, however, if rescuing or pharmacologically 206 
enhancing rhythmicity in peripheral clocks could become a relevant treatment 207 
option in chronic diseases. 208 
Interactions between the circadian clock and the cell-cycle 209 
Possible consequences of clock disruption include a higher incidence of 210 
cancer and accelerated cancer progression. In experimental cancer models, 211 
SCN ablation or simulated shift-work schedules have been shown to 212 
accelerate tumor growth [25, 71]. In patients, epidemiological evidence 213 
suggests that shift workers have higher cancer incidences and breast cancer 214 
patients with misaligned sleep tend to have shorter disease free survival [72-215 
74]. This reflects in part the tight link between cell cycle and the circadian 216 
clock. The cell cycle has long been known to be synchronized by the CTS in 217 
mammals [75]. Twenty-four-hour rhythms have been demonstrated in DNA 218 
synthesis and mitotic activity in vitro in many cells and in vivo in many rodent 219 
and human tissues [9, 76-78]. Moreover, circadian synchronized cell cycling 220 
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has been recognized as an important mechanism accounting for the 221 
chronotoxicity of some anticancer drugs, such as gemcitabine, irinotecan, 5-222 
fluorouracil or docetaxel [10, 79]. Based on studies in mouse liver and in 223 
cultured fibroblasts, a gating mechanism controlling the G2/M transition via 224 
CLOCK/BMAL1-activated WEE1 kinase was initially considered. Subsequent 225 
studies have suggested further mechanisms by which the clock and the cell 226 
cycle are coupled [80-83]. As such, a common theme emerges: the circadian 227 
clock controls the expression of several cell cycle-related genes, which in turn 228 
modulate the expression of key regulators of mitosis. The combination of 229 
long-term clock and cell cycle reporter recording at the single cell level has 230 
further shown, using mathematical modelling, that the circadian clock and the 231 
cell cycle should be considered coupled oscillators, with reciprocal 232 
interactions [1, 5]. This suggests that the clock can control cellular 233 
proliferation, but also that cellular proliferation can influence the clock. This 234 
relationship could further represent a critical determinant for the time-235 
dependencies of the cell cycle effects of many drugs and environmental 236 
toxicants. However, whether such coupling also exists in vivo, displays any 237 
tissue specificity, or is altered in proliferative diseases remains unknown as 238 
yet. 239 
Role of circadian clocks in pharmacology and toxicology 240 
Twenty-four-hour rhythms have long been known to moderate xenobiotic 241 
absorption, distribution, metabolism and excretion. These key processes 242 
determine the shape and levels of cellular exposure to drugs and toxicants, 243 
i.e., pharmacokinetics and toxicokinetics [10]. An epidemiologic study 244 
involving 14480 patients with intentional self-poisoning (oleander seed or 245 
organophosphorus) further highlights the tight links between the time of 246 
poisoning and death in the human population. Up to 50% reduction in case 247 
fatalities were observed if evening rather than late morning poisoning 248 
occurred; a difference that does not seem to be explained by the treatment 249 
but was suggested to be influenced by intestinal P-glycoprotein (P-gp) and 250 
hepatic cytochrome P-450 (CYP) 3A4 rhythms [84]. 251 
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There are recent advances in the understanding of the phases of circadian 252 
control of xenobiotic metabolism, namely, Phase I, oxidation, reduction and 253 
hydrolysis reactions; Phase II, conjugation reactions; and Phase III, xenobiotic 254 
transport. These processes have been shown to ultimately increase 255 
xenobiotic water solubility and excretion mainly via urine and bile [10, 79].  256 
Phase I and II metabolism in mouse liver, kidney and intestine have been 257 
shown to be regulated through rhythmic expression of E-box dependent 258 
proline and acidic amino acid-rich basic leucine zipper transcription factors 259 
(PARbZip) [85]. PARbZip transcription factors bind rhythmically to D-box 260 
containing promoters of key genes that regulate xenobiotic metabolism, such 261 
as cytochrome P450 oxireductase (POR), constitutive androstane receptor 262 
(CAR), peroxisome proliferator activated receptor-α (PPAR-α), and aryl-263 
hydrocarbon receptor (AhR) [85]. Moreover, microsomal and non-microsomal 264 
oxido-reductases and esterases also display circadian rhythms not only in 265 
mRNA and protein, but also at the enzymatic activity level. As mentioned 266 
above, circadian modulation of CYP activity results in dosing time and 267 
functional hepatic clock-dependent differences in acetaminophen toxicity in 268 
mice [58, 59]. Acetaminophen is metabolized by CYP3A4, and human 269 
CYP3A4 is important for the biotransformation of half of all marketed drugs. 270 
Indeed, in healthy human subjects, CYP3A4-dependent metabolism of the 271 
benzodiazepine derived anxiolytic midazolam is 20% higher in the middle of 272 
the day when compared to the middle of the night [86].  273 
Carboxylesterases (CES) also play a pivotal role in Phase I metabolism and 274 
are under direct transcription control of PARbZip proteins as has been found 275 
in vitro [87] and in vivo [85]. Indeed, the rhythmic control of CES has been 276 
shown to be important for the circadian bioactivation of anticancer agents 277 
such as irinotecan and capecitabine [79]. Another important Phase I enzyme, 278 
dihydropyrimidine dehydrogenase (DPYD) is circadian regulated, resulting in 279 
time-dependent dehydrogenation and deamination of fluoropyrimidine drugs, 280 
such as fluorouracil and capecitabine [79], respectively. 281 
With regard to Phase II drug metabolism, the circadian rhythms of glutathione 282 
S-transferase (GST) activity and glutathione (GSH) content have been 283 
reported to be highly important for the detoxification of xenobiotics as is the 284 
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case for instance, of acetaminophen [60], or metal compounds such as 285 
cadmium [88] or platinum complexes. In rodents, the GSH contents in the liver 286 
and jejunum are approximately threefold higher during the second half of the 287 
night when compared to mid-day [89]. In support of this, PARbZip-deficient 288 
mice exhibit a general down-regulation of Gstt1 and Gsta3 gene expression 289 
and are subsequently less susceptible to acetaminophen toxicity [85]. 290 
Following solubilisation, Phase III transport of compounds in the liver, kidney 291 
and intestine are mainly accomplished by ATP binding cassette (ABC) 292 
transporters [90]. Many ABC transporters including abcb1a, abcb1b (the 293 
rodent homologs of P-gp) and other ABC members abcc2 and abcg2 have 294 
been shown to exhibit circadian expression patterns in the intestine and liver 295 
in rodent models [91-98]. Transcriptional rhythms have also been 296 
demonstrated to lead to higher daytime P-gp activity in the jejunum and ileum 297 
of rats [99]. Solute carrier (SLC) superfamily transporters, are mainly 298 
responsible for drug influx into the intestine, liver, kidneys [90]. In mice, 299 
hepatic circadian expression patterns have been observed in various organic 300 
anion transporting polypeptides, the organic anion transporter-1 (Oct1)and 2 301 
(Oct2)[92]. In addition, rhythmic PPAR-α driven OCT2 protein abundance has 302 
been implicated as an important regulator of the circadian rhythm of cisplatin 303 
nephrotoxicity in mice [100]. 304 
The daily variation of enzyme and transporter activity involved in the 305 
metabolism of a given substance is a striking observation. For instance, both 306 
in vitro and in vivo, the maximum in the bioactivation of irinotecan by CES 307 
occurs near the nadir in its detoxification enzyme UGT1A, and vice versa 308 
[101]. In aggregate, the circadian coordination of Phase I, II and III xenobiotic 309 
metabolism and transport pathways represents an anticipatory timing 310 
mechanism that most efficiently helps to increase xenobiotic water solubility 311 
and excretion [79]. Such endogenous circadian organisation likely reflects the 312 
adaptation of living beings to environmental 24 h cycles in possible xenobiotic 313 
exposure. 314 
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A New Way Forward: In Vitro-In Silico Circadian Modulation of Xenobiotics Effects 315 
The tight coordination of metabolic pathways across the day shows strong 316 
inter-individual variance, but also can be altered, in particular whenever 317 
pathologic processes or treatments disrupt the CTS. Therefore, there is a 318 
need for a systems approach to chronopharmacology in order to 319 
systematically map the key clock-controlled metabolic processes and test the 320 
consequences of their alterations on chronopharmacology. Expectedly, such 321 
systems chronopharmacology will help make a priori, predictions of the 322 
specific chronopharmacology pattern of a given substance, according to an 323 
individual’s CTS as assessed by one or more suitable biomarkers. A first step 324 
toward this new strategy has been to combine in vitro and in silico 325 
investigations. For instance, in contrast to chronopharmacology or 326 
chronotoxicology studies in vivo, investigations in circadian synchronized cell 327 
culture models presently allow systematic and quantitative testing of drug 328 
compounds, subsequently generating mathematical models to quantify the 329 
impact of molecular clocks on xenobiotic metabolism (24). An example is the 330 
in vitro–in silico circadian investigation of the cancer chemotherapeutic 331 
irinotecan pharmacokinetics-pharmacodynamics, which were performed in 332 
differentiated human epithelial colorectal adenocarcinoma (Caco-2) cells [87, 333 
101]. Results showed that transcriptional rhythms were observed in all phases 334 
of irinotecan metabolism: Phase I (CES), II (UGT1A1) and III (ABCB1) [101]. 335 
For example, the CES-mediated biotransformation of irinotecan into its active 336 
metabolite SN38, doubled depending on the circadian phase cells were 337 
exposed to irinotecan. All these effects taken together, this led to a 4-fold 338 
change of irinotecan-induced apoptosis depending on the timing of drug 339 
exposure. When the circadian clock was disrupted by siRNA mediated Bmal1 340 
silencing, however, drug timing dependent rhythms of drug metabolism and 341 
apoptosis were absent [101]. These findings illustrate how in vitro 342 
chronopharmacology and chronotoxicology might contribute to a cost-effective 343 
optimisation of preclinical drug development and/or toxicant testing.  344 
Each on their own, different in vitro systems might reveal further differences in 345 
circadian dynamics of drug metabolism, potentially revealing cell or tissue 346 
specificity and proliferation status or inter-individual differences irrespective of 347 
Dallmann et al.:    12 
comparable molecular clock proficiency. For example, by contrast to Caco-2 348 
cells, clock-containing proliferating Glasgow osteosarcoma cells did not 349 
exhibit a circadian pattern in abcb1a or abcb1b gene expression [102]. 350 
Usefulness of Circadian “Omics” 351 
The in vivo and in vitro drug metabolism circadian investigation approaches 352 
might indeed benefit from “omics” technologies. Multiple pharmacology and 353 
toxicology studies have shown that circadian clocks regulate key molecular 354 
pathways of drug metabolism in animal models. For studies of liver drug 355 
metabolism, various recent transcriptomic, proteomic and metabolomic 356 
circadian data-sets are now available from mice [103-107]. This has been 357 
extremely useful for systems biology approaches to drug metabolism. 358 
However, fewer time-series studies have been published in other putative 359 
drug target tissues such as the heart and aorta [27, 108, 109], the kidney 360 
[110] or the central pacemaker, the SCN [111]. Comparing circadian patterns 361 
of multiple tissues is especially interesting and informative because it casts 362 
insight into tissue-specific clock-controlled mechanisms of xenobiotic 363 
metabolism. For example, circadian expression profiles of more than half of all 364 
nuclear receptor genes, (which represent important metabolic sensors in key 365 
tissues such as the liver, skeletal muscle and fat) have established a clear 366 
tissue-specific circadian regulation of energy metabolism in mice [112]. 367 
However, only one drug metabolism study has been conducted to compare 368 
circadian gene expression in a dozen mouse tissues [106]. The resulting data 369 
suggest that many disease-relevant genes operate under the control of 370 
circadian clocks, but also, that many drug targets are circadian genes 371 
themselves. In fact, a large portion of marketed drugs has effects on circadian 372 
genes, with a half-life of less than 6 h [106]. This could be conducive for the 373 
development of chronotherapeutic approaches for these compounds. Key 374 
drug metabolism pathways have important roles in extra-hepatic functions. 375 
For example, the human CYP-P450 system, contributes to the bioactivation of 376 
multiple drugs in intestinal and respiratory tissues, and is highly regulated by 377 
molecular clocks with tissue-dependent phases of gene expression [113]. Of 378 
note, circadian metabolomics have been recently described in various 379 
biological samples such as blood, saliva, urine and exhaled breath [114-119]. 380 
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These matrices might offer great translational potential as biomarkers for the 381 
clinic because they are available from animals and human subjects alike [114-382 
117, 120], and facilitating non-invasive repeat sampling [118, 119], in time-383 
series or “round-the-clock” data-set collection. 384 
Effects of Drugs on the CTS  385 
The CTS modulates drug pharmacology and toxicology through a multitude of 386 
processes. There is growing evidence of the effects of drugs on the CTS, as 387 
shown by the circadian disruption of rest-activity, body temperature or clock 388 
gene expression patterns. In mice and human patients receiving 389 
chemotherapeutic drugs severe alterations of physiological rhythms have 390 
been observed [6, 121, 122]. Broadly, these drugs can be grouped into (i) 391 
those exhibiting unintentional side-effects or unspecific toxicity, resetting the 392 
clock, and (ii) targeted chronodrugs. With a promising outlook, new agents 393 
such as RevErb agonists [123] are currently being developed to target either 394 
CTS coordination or the molecular clock for different tissues in order to 395 
enhance the robustness of these components and/or modify circadian 396 
phases. Moreover, mathematical modelling of core clock genes Bmal1 and 397 
RevErbα expression patterns in mouse liver or colon, have proved to be 398 
predictive of different chronotoxicity patterns for the drug irinotecan [20]. 399 
Effects of Xenobiotics on the CTS 400 
Chemotherapeutic drugs in particular have been described to have resetting 401 
and dampening effects on circadian oscillations. These agents can also 402 
unintentionally modify the CTS by either disrupting CTS coordination, or by 403 
altering circadian amplitude or phase. As such, the CTS can represent a 404 
toxicity target worth to be shielded through proper circadian drug timing. 405 
Indeed, certain indicators of CTS coordination such as rest/activity and core 406 
body temperature can be severely disrupted by anticancer agents of any 407 
pharmacologic class in mice or rats [reviewed in 79]. Twelve anticancer 408 
agents including cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, irinotecan, 409 
seliciclib, and everolimus among others, have been shown to impair molecular 410 
circadian clocks in the SCN, liver, adrenals, and other peripheral organs of 411 
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mice and in cell cultures [79]. Moreover, the extent of the alterations and the 412 
recovery dynamics of rest-activity and body temperature rhythms depend on 413 
dose as well as on circadian timing [124]. Thus, inappropriately timed 414 
anticancer agents are capable of modifying circadian clock amplitude and 415 
phase in peripheral organs, preventing the predictability of internal circadian 416 
timing. Indeed, the clinical relevance of treatment-induced circadian disruption 417 
has been demonstrated in cancer patients receiving chemotherapy, and using 418 
the rest-activity rhythm as a CTS “biomarker” [122, 125]. 419 
Chronodrugs – Clocks as Targets 420 
The hidden resetting of clocks by drugs presents a problem in terms of proper 421 
timing for repeated daily dosing. Interestingly, the dosing-time dependent 422 
toxicity persists or is even amplified during the chronic dosing of anticancer 423 
agents such as taxane derived docetaxel, the alkylators carboplatin and 424 
oxaliplatin, or the cyclin-dependent kinase inhibitor seliciclib [79]. This finding 425 
is in line with the dosing time dependency of drug-induced circadian 426 
disruption. However, targeting specific agents at the CTS might counteract the 427 
disruptive effects of some drugs through purposely resetting circadian 428 
rhythms to a specific phase and/or by enhancing their amplitudes. Such is the 429 
case for drugs that act on the neuronal network of the master pacemaker in 430 
the SCN. The SCN is reset by guanylyl cyclase-cGMP-protein kinase G 431 
dependent mechanisms, which have been described more than a decade ago 432 
[126]. More recently, this pathway has been exploited using “sub-erectile” 433 
doses of the cGMP-specific phosphodiesterase type-5 (PDE5) inhibitor 434 
sildenafil to alleviate jet-lag and shorten physiological adaptations following 435 
trans-median travel [127]. Similarly, it has been suggested that faster 436 
circadian resetting could result from pharmacological uncoupling of the SCN 437 
neuronal network. Desynchronised SCN neurons because of their smaller 438 
combined amplitude would then be more easily reset to the new phase [128]. 439 
Even more classical, yet mechanistically not fully understood, the pineal 440 
hormone melatonin is known to reset the circadian clock. Recently, 441 
melatoninergic agent like ramelteon and combined 442 
melatoninergic/serotonergic drugs like agomelatine have become available in 443 
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the clinic to treat insomnia and depression, respectively. Like melatonin, their 444 
mechanism of action might involve a resetting effect on the SCN clock 445 
mediated by the melatonin receptors MT1 and MT2 [129, 130]. Another 446 
example is lithium, a marketed drug used in the treatment of bipolar disorders 447 
that has been shown to lengthen the period of the circadian clock. Most likely 448 
through inhibition of glycogen synthase kinase 3 beta (GSK3β) which leads to 449 
stabilisation of CRY2 and faster degradation of REV-ERBα protein levels 450 
[131]. 451 
Further compounds have been described as targeting the core clock genes; 452 
most prominently, direct or indirect modulators of casein kinase 1 [132, 133] 453 
but also RevErbα [134] and retinoic acid receptor-related orphan receptor α/γ 454 
(RORα/γ) [135] protein products. In recent years, multiple high throughput 455 
forward screening (HTS) in vitro projects have been undertaken to find novel 456 
chronomodulatory small molecules. So far, modulators for three targets have 457 
been reported: RevErbα, Cryptochrome, and Casein kinase 1 [32, 136-139]. 458 
For these experiments, circadian real-time reporter expressing cell lines, 459 
mostly the human osteosarcoma cell line U2OS have been used. Among 460 
these agents, the CRY modulators have already been translated into clinical 461 
Proof-of-Concept trials in two indications, Cushing syndrome and Diabetes 462 
mellitus type 2. It remains to be seen, which of the discovered mechanisms of 463 
action will effectively prove to be useful in a clinical setting and whether clock 464 
alterations do not lead to unsuspected adverse events.  465 
Concluding Remarks  466 
Circadian clocks modulate many molecular pathways of human physiology 467 
and pathophysiology. An increasing amount of evidence indicates that there is 468 
a biologically and medically relevant impact of time-of-day on 469 
pharmacotherapy. Recent chronopharmacology studies involving cancer, 470 
rheumatolology, hematology, neurologic /psychiatric disorders and 471 
cardiovascular medicine have been undertaken (Tables 1&2). Indeed, 472 
circadian clocks modulate many processes that define drug properties and 473 
behaviour. There have been a few successes in the clinical translation of 474 
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chronotherapy, but nevertheless, the medical community, drug developers 475 
and, importantly, regulatory agencies, have yet to embrace circadian timing as 476 
an important factor modulating both the efficacy and safety of 477 
pharmacotherapy. The identification of reliable and cost-effective biomarkers 478 
of the CTS might indeed represent the major effort that is required to fulfil the 479 
already documented promise of chronotherapy for improving outcomes of 480 
patients with various diseases. As such, this is an exciting era to be integrated 481 
into the development of both new drugs, and new clock-based therapeutic 482 
strategies. Our ability to pharmacologically target the CTS to alleviate or treat 483 
certain chronic diseases will bring the next step in fully implementing the 484 
concept of chronomedicine (see Outstanding Questions).  485 
  486 
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Figure Legends 490 
Figure 1: The cell-autonomous circadian clockwork (left) is the 491 
functional unit of the circadian timing system, and determines the 492 
complex interaction with xenobiotic metabolism.  493 
(Left) Simplified core circadian oscillator (See Box 1 for details and 494 
abbreviations) and one output relevant for xenobiotic metabolism through 495 
control of aminolevulinic acid synthase 1 (ALAS1), constitutive androstane 496 
receptor (CAR) and cytochrome P450 oxidoreductase (POR). 497 
(Right) The CTS involves a central hypothalamic pacemaker – the 498 
suprachiasmatic nuclei (SCN) – which coordinates clocks in all the cells in the 499 
body through the generation of an array of physiological rhythms such as rest-500 
activity, body temperature and hormonal secretions. The SCN synchronises 501 
the peripheral clocks relative to each other and to the environmental time 502 
cues provided by the day-night and social cycles (blue box). Following 503 
exposure of an organism to a xenobiotic, the substance undergoes the 504 
classical Absorption, Distribution, Metabolism and Elimination (ADME) 505 
processes. All of these processes, which will ultimately determine the toxicity 506 
or pharmacologic effect of the xenobiotic are regulated by peripheral and 507 
central clocks present in the gut, heart and blood vessels, liver and pancreas, 508 
as well as kidney and colon. Xenobiotics can also reset the molecular clock or 509 
CTS through direct interference with the molecular clock or by altering or 510 
disrupting physiological pathways.  511 
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Tables 512 
 513 
Table 1. Recent examples of medications with chronopharmacologic effects and corresponding clock-controlled metabolic 514 
pathways. Abbreviations: dosing routes p.o., oral; i.v. intravenous; i.t., intratracheal; i.p., intraperitoneal; LLC: lewis lung 515 
carcinoma; Ref reference; ZT zeitgeber time; Cmax peak plasma concentration; >> higher/better/more than. 516 
Agent (Target) Circadian modulation Dosing, species Main findings Ref 
Erlotinib 
(Tyrosine kinase 
inhibitor, anticancer 
drug) 
EGFR, Ras/Raf/MAPK & 
PIK3/AKT (tumour) 
5 mg/kg/d p.o., subchronic 
Mouse (female) with Hec827 
xenograft 
Tumour inhibition ZT1 >> ZT13 [140] 
Cyp3a11, Cyp3a13, Cyp1a2 
(liver) 
3 mg p.o., single dose 
Mouse (female) with LLC 
xenograft 
Systemic exposure ZT1>>ZT13 [141] 
Sunitinib 
(Tyrosine kinase 
inhibitor, anticancer 
drug) 
Cyp3a11 (Liver, duodenum, 
jejunum) 
abcb1a (Liver, duodenum, 
jejunum, lung) 
1.06 mg p.o., single dose 
Mouse (female) 
Systemic and liver exposure to 
sunitinib ZT20>ZT0 
SUI112 (metabolite) ZT8>ZT12 
[142] 
(elimination)* 25 mg p.o., single dose 
Rabbit (male) 
Cmax and systemic exposure to 
sunitinib and SUI12662 (metabolite): 
ZT1>>ZT13 
Clearance faster after ZT13 dosing 
[143] 
Lapatinib 
(dual tyrosine kinase 
inhibitor interrupting the 
HER2/neu and EGFR 
pathways, anticancer 
drug) 
EGFR/Ras/Raf/MAPK 
Errfi1, Dusp1 (liver) 
Hbegf, Tgfα, Eref (liver) 
40 mg/kg/d, p.o., subchronic 
Mouse (male) EGFR/HER2 
driven tumour 
Tumour and angiogenesis inhibition 
ZT23>>ZT13 
[19-22] 
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Roscovitine 
(seliciclib, CDK inhibitor, 
anticancer drug) 
Cyp3a11, Cyp3a13 (liver) 300 mg/kg/d p.o., single 
Mouse (male) 
Systemic, kidney, adipose tissue 
exposure ZT3>>ZT19 
Liver metabolic ratio ZT19>ZT3 
[144] 
Everolimus 
(mTOR inhibitor, 
anticancer drug, 
immunosuppressant) 
mTOR/Fbxw7/P70S6K 
(tumour) 
20 mg/kg i.v., single 
Mouse (male) w/o renal cell 
tumour 
Plasma PK ZT12 = ZT0 
Antitumour efficacy ZT12 >>ZT0 
[145] 
Irinotecan 
(Top1 inhibitor, 
anticancer drug) 
Ces2, Ugt1a1, abcb1a, 
abcb1b (liver and ileum), 
abcc2 (ileum) 
50-80 mg/kg i.v., single or 4d 
repeat dosing 
Mouse (male & female, 
4 strains) 
Least toxic time and chronoPK-PD 
relation dependent on sex and strain 
ZT7, ZT11 or ZT15 
[20] 
Tamoxifen 
(antiestrogenic,, 
anticancer drug) 
Cyp2d10, Cyp2d22, Cyp3a11 
(liver) 
4 mg p.o., single 
Mouse (female) 
Plasma and liver exposure 
ZT18>=ZT6 (trend) 
[146] 
Pethidine 
(analgesic opioid) 
N-demethylation* 20 mg/kg/d i.p., single or 5 d 
Mouse (male) 
Analgesic effect & metabolism ZT15 
> ZT3 
[147] 
Bleomycin 
(toxicant and anticancer 
drug) 
NRF2/glutathione  
antioxidant defense 
1 mg/kg i.t., single 
Mouse (female) 
Pulmonary fibrosis ZT12>>ZT0 [148] 
Tolbutamide 
(antidiabetic) 
Glucose transporter 4 
(GLUT4) 
5-10 mg/kg i.v., single 
Rat (male) 
Hypoglycaemia ZT12>>ZT0 [149] 
Isoniazid 
(antituberculous 
antibiotic) 
(N-acetyltransferase 2-NAT2 
and Cyp2e1)* 
120-180 mg/kg i.p., single 
Mouse (male) 
Gross and hematologic toxicities 
ZT1<ZT9 
[150] 
Acetaminophen 
(analgesic) 
Cyp2e1, Por (liver)  250 mg/kg, i.p. single 
Mouse (male) 
Toxicity ZT2<<ZT14 [58, 59, 
151] 
Pentobarbital (hypnotic, , 
antiepileptic) 
Por (liver) 50-60 mg/kg, i.p. single 
Mouse (male) 
Sleep time ZT2>>ZT14 
Clearance ZT2<ZT14 
[59] 
*Pathways or enzymes indicate suggested mechanisms for effects 517 
 518 
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Table 2. Recent clinical chronotherapy studies. Abbreviations: pts, patients; 5-FU-LV, 5-fluorouracil-leucovorin; I-OHP, 519 
oxaliplatin; PK pharmacokinetics; N, number of subjects; M, male; F, female; AUC, Area under the curve; Cmax, peak plasma 520 
concentration; gr, grade; Cthrough, Minimum drug concentration in blood/plasma in multiple (subsequent) dosing at steady-state condition.  521 
Disease  Drug(s) (dose, 
route) 
Study 
design 
Dosing schedule N  Main findings Ref 
Breast cancer 
(hormone 
receptor 
receptive) 
Tamoxifen  
(20 or 40 mg p.o.) 
PK cross 
over 
8:00 vs 13:00 vs 20:00 
(4 weeks on each 
dosing time) 
27 F Mean Cmax and AUC0-8h 
of tamoxifen and endoxifen (bioactive 
metabolite) 
8:00 >> 20:00 (by ≈ 20%) 
Mean tmax 8:00 < 20:00 
High CYP2D6 metabolism may 
enhance circadian effect 
[146] 
Renal cell cancer, 
gastrointestinal 
stromal, or 
pancreatic neuro-
endocrine 
tumours 
Sunitinib (stable once 
daily dose for > 2 
weeks before entry)  
PK 
randomized 
cross over  
8:00 vs 18:00 (3 weeks 
on each dosing time) 
Additional testing of 
13:00 for pts subset 
27 pts 
(22 M, 
5 F) 
12 pts: 
3 
dosing 
times 
Mean concentration at time of 
subsequent dose intake (Ctrough) ) : 
(13:00 = 18:00) > 8:00 
No difference in AUC 
[142] 
Non small cell 
lung cancer 
(advanced) 
Cisplatin 
(20mg/m²/d x 4d, 
combined with 
docetaxel or 
gemcitabine) 
Randomized 
Phase II with 
minimization 
6:00 vs 18:00 41 pts 
(28 M, 
13 F) 
Neutropenia gr 3-4: 
12% at 18:00 vs 33% at 6:00 
Nausea gr 1-2: 18:00 < 6:00 
Total and unbound cisplatin clearance 
18:00 > 6:00 
[152] 
Metastatic 
colorectal cancer  
5-FU-LV and l-OHP 
(5-FU 3000-3600 
mg/m², LV 1200 
mg/m², l-OHP 100 
mg/m², q 2 wks 
International 
randomized 
Phase III 
(post hoc 
analysis) 
Fixed chronomodulated 
delivery (chronoFLO4) 
vs conventional delivery 
(FOLFOX2) 
556 pts  
(331 M, 
225 F) 
Neutropenia 
- All grades: chronoFLO4, 33%, 
FOLFOX, 61% 
- Grade 3-4: chronoFLO4, 7% 
FOLFOX, 25% 
- More frequent in women 
- Predictive of a better survival for 
FOLFOX2, not chronoFLO4 
[153] 
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Metastatic 
colorectal cancer  
5-FU-LV and l-OHP 
(5-FU 3000-3600 
mg/m², LV 1200 
mg/m², l-OHP 100 
mg/m², q 2 wks 
International 
randomized 
Phase III 
(post hoc 
analysis) 
Fixed chronomodulated 
delivery (chronoFLO4) 
vs conventional delivery 
(FOLFOX2) 
556 pts  
(331 M, 
225 F) 
Neutropenia 
- All grades: chronoFLO4, 33%, 
FOLFOX, 61% 
- Grade 3-4: chronoFLO4, 7% 
FOLFOX, 25% 
- More frequent in women 
- Predictive of a better survival for 
FOLFOX2, not chronoFLO4 
[153] 
 5-FU-LV and l-OHP 
(5-FU 3000-
3600mg/m², LV 1200-
1500mg/m², l-OHP, 
100-125mg/m², q 2-
3wks) 
Meta-
analysis of 3 
international 
Phase III 
randomized  
ChronoFLO vs 
Conv (FOLFOX2 or 
constant rate infusion) 
842 pts 
(497 M, 
345 F) 
Sex-dependent efficacy of optimal fixed 
schedule : 
- Median survival Male: 
 ChronoFLO: 20.8 mo 
 Conv : 17.5 mo 
- Median survival Female: 
 ChronoFLO: 16.6 mo 
 Conv : 18.4 mo 
- Same sex- schedule interaction for 
progression-free survival and tumour 
response rate in pooled analysis and 
for each randomized trial. 
[154] 
Rheumatoid 
arthritis (RA) 
Low dose modified 
release prednisone (5 
mg, MR prednisone) 
12-week 
double-blind 
placebo-
controlled 
randomized 
(CAPRA2) 
Evening intake vs 
placebo combined with 
existing RA disease –
modifying antirheumatic 
drug (DMARD) 
treatment 
350 pts - 20% improvement in RA signs and 
symptoms: MR prednisone: 48% vs 
Placebo: 29% 
- 50% improvement: MR prednisone: 
22% vs Placebo: 10% 
[155] 
MR prednisone vs placebo: 
- reduced fatigue 
- improved SF 36 vitality score and 
other well-being parameters 
[156] 
Adrenal 
congenital 
hypoplasia 
Chronocort  
(10 mg at 7:00 
and 20 mg at 23:00) 
PK Phase II Unequal dosing 
morning and evening 
16 pts 
(8 M, 
8 F) 
- Good approximation of circadian 
physiologic secretion  
- Good tolerability and effectiveness in 
controlling androgen excess 
[157] 
Dallmann et al.:  22 
Chronic kidney 
disease 
Valsartan 
(80-320 mg p.o.) 
Randomized Bedtime vs awakening 60 pts 
(non 
dipper) 
30 pts 
(dipper) 
Non dippers on bedtime vs awakening 
Valsartan: 
- greater reduction in proteinuria 
- better glomerular filtration rate  
- better protection against myocardial 
hypertrophy 
[158] 
 Blood pressure 
lowering agent 
Systematic 
review of 7 
trials  
Bedtime vs no bedtime 1277 
pts 
BP lowering medication at bedtime 
reduced total events and major 
cardiovascular events 
Non significant reduction of death rate 
(p ≈ 0.06) 
[159] 
Atherothrombosis 
(post myocardial 
infarction) 
Clopidogrel (75 mg 
p.o.) and aspirin (75 
mg p.o.) 
Randomized 6:00 vs 10:00 vs 14:00 
vs 19:00 for 4 days on 
each dosing time 
59 pts  
(45 M, 
14 F) 
Platelet inhibition lowest after dosing at 
10:00 
Non responsiveness: 2.4-fold more 
frequent at 10:00 vs 6:00 
[160] 
Osteoporosis 
(postmenopausal) 
Raloxifene 
(estrogen receptor 
modulator, 60 mg 
p.o.) 
Randomized Morning vs evening  
for 12 months 
39 
healthy 
(F) 
Plasminogen activation inhibitor1: 
Morning dosing: +40% 
Evening dosing: -0.3% 
In favour of increased risk of venous 
thromboembolism after morning dosing 
[161] 
Endogenous 
coagulation 
Rivaroxaban 
(anticoagulant agent, 
10 mg p.o.) 
Randomized 
controlled 
cross over 
Morning vs evening  
for 3 days 
16 
healthy 
Plasma concentration 12 h after dosing: 
Evening : 53.3 ng/mL 
Morning : 23.3 ng/mL 
Evening dosing: better matching 
physiologic morning hypo-fibrinolysis 
[162] 
       
 522 
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Text Boxes 523 
Text Box 1: The Molecular clockwork 524 
The unit of the molecular circadian oscillator is the cell. At the core of this cell-525 
autonomous molecular mechanism driving circadian cycles are two 526 
interlocked transcriptional/translational feedback loops. The mechanistic 527 
principle of a circadian clock is rather simple: an activator gene initiates 528 
transcription of a repressor gene. Then, the repressor protein re-enters the 529 
nucleus and eventually shuts off its own transcription until the repressor is 530 
degraded and the cycle can start again [163]. In mammals, Bmal1 is the key 531 
transcriptional activator. BMAL1 binds to regulatory E-box elements as a 532 
complex with its dimerization partners CLOCK or NPAS2 [164] and activates 533 
the transcription of Period (Per) and Cry (Cryptochrome) genes. After 534 
translation, PER and CRY proteins re-enter the nucleus and as part of a large 535 
complex repress their own transcription [165]. Once the repressor complex 536 
dissociates, the cycle can start once more. A second loop stabilizes this basic 537 
loop: as in the case of Pers and Crys, RevErbs and ROR orphan nuclear 538 
receptor family genes are activated by the BMAL1 containing complex binding 539 
to the E-box on their promoters. In turn, ROR and REVERB proteins 540 
competitively bind to ROR-elements, activating and repressing Bmal1 541 
transcription, respectively [166]. Most important for the usefulness of any 542 
clock are its hands, i.e., the output. In mammals, about 20-40% of the 543 
transcriptome [106], proteome [104, 105] and metabolome [114, 116] are 544 
modulated by the circadian clock. Importantly, many rate-limiting steps of key 545 
physiological pathways including those important for drug pharmacokinetics 546 
and pharmodynamics are under direct or indirect clock control [10, 106, 167]. 547 
Post-transcriptional modifications of RNA [168], the regulation of ribosomal 548 
translation [169, 170] as well as post-translational control by kinases, 549 
phosphatases and acetylases have been implicated in the daily variation and 550 
tuning of the circadian clock [171, 172]. Possibly completely independent of 551 
the transcriptional feedback loop, non-transcriptional oscillators have been 552 
described; for example, the peroxiredoxin oscillations in human red blood 553 
cells [173]. 554 
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Glossary Box 555 
 Circadian Timing System (CTS), In mammals, the circadian timing 556 
system consists of three levels of interacting mechanisms: (i) the cell-557 
autonomous molecular circadian clock, (ii) the suprachiasmatic nuclei 558 
(SCN), and (iii) physiological rhythms. 559 
 Circadian rhythm, A temperature compensated biological rhythm with 560 
a period of about one day (lat. circa, about; dies, day), which persists in 561 
constant conditions without any time cues, i.e., is endogenous. 562 
 Core clock genes, are an integral part of the core clock mechanism 563 
and most of them physically interact with one another (Box 2). In 564 
mammals they are to some degree redundant (e.g., Pers, Crys). 565 
Knock-out studies in mice suggest that all of them are important for 566 
proper clock function, at least in some tissues. In comparison, clock-567 
controlled genes, are genes with significant circadian modulation in 568 
their expression profile that do not feedback on the clock mechanism 569 
themselves. Typically, these genes are driven by promoter elements 570 
like E- or D-box elements, but might also contain further tissue-specific 571 
regulatory elements that lead to tissue-specific inducibility.  572 
 Physiological rhythms, provide the endogenous time cues needed for 573 
the daily coordination and resetting of cellular clocks in the peripheral 574 
tissues of an organism. 575 
 Chronotype, or the diurnal preference of an individual is based at least 576 
partially genetically determined, but is plastic to a certain degree. 577 
Previously, variation of chronotype with age, sex and behaviour (e.g., 578 
shift-work, habits) have been described.  579 
 Xenobiotic, a chemical compound such as a drug, a toxicant, a 580 
pesticide, or a carcinogen that is foreign to a living organism. 581 
 Suprachiasmatic nuclei (SCN) or central clock, this paired structure 582 
in the ventral hypothalamus is indispensible for generating most 583 
consolidated circadian physiological and behavioural rhythms. They 584 
are considered the central pacemaker and receive light input from the 585 
retina and synchronise the organism with environmental day/night 586 
cycles. In contrast, peripheral clocks are all non-SCN tissues or 587 
organs.  588 
 Non-photic signals, cues other than the alternation of light and 589 
darkness. Food, activity and few other so-called zeitgeber have been 590 
shown to be able to influence the circadian system and if rhythmically 591 
presented synchronise the CTS. 592 
 Circadian amplitude and phase are two parameters which 593 
characterise the extent of variation and the timing of a rhythm with an 594 
about 24-hour period.  595 
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 1121 
Trends Box 1122 
 The Circadian Timing System (CTS) significantly modulates efficacy and 1123 
toxicity of many xenobiotics and therefore, time-of-day is an important 1124 
variable to consider for many marketed drugs, as well as drugs under 1125 
development, and environmental toxicant exposure. 1126 
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 Cell-autonomous circadian oscillations in peripheral tissues have been 1127 
shown to play essential roles in time-of-day variations, and might present 1128 
novel targets for pharmacotherapy. 1129 
 Lifestyle, sex, age, genotype, disease, and xenobiotic effects can shape 1130 
and alter CTS dynamics, including clock-controlled metabolism pathways.  1131 
 Recent small molecule drug screens have identified several compounds 1132 
that target the circadian clockwork itself, and might be useful to treat 1133 
circadian desynchronisation due to disease or other drug or toxicant 1134 
effects.  1135 
Outstanding Questions Box 1136 
 The pharmaceutical industry should consider the integration of 1137 
chronopharmacology into new drug development as a competitive 1138 
advantage for safer and more effective medications. Similarly, 1139 
regulatory agencies should request circadian timing studies to 1140 
complement dose-effect and safety studies of pharmacological agents. 1141 
Which scientific and biomedical framework will prompt this to happen? 1142 
 How will Circadian Timing System status and clock phase be reliably 1143 
assessed using minimally invasive single sampling procedures in a 1144 
given tissue in human patients, in order to predict optimal treatment 1145 
timing? 1146 
 Will in vitro chronopharmacology/chronotoxicology provide a robust tool 1147 
for the identification of xenobiotic timing with best tolerability and/or 1148 
optimal efficacy?  1149 
 Will a comprehensive systems medicine approach help integrate 1150 
potential CTS-modifiers, including disease, lifestyle, aging, sex and 1151 
genetics to achieve optimal personalized drug dosage and timing? 1152 
